Literature DB >> 29939178

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation.

Jayanth S Shankara Narayanan1, Partha Ray1, Ibtehaj Naqvi2, Rebekah White3.   

Abstract

Pancreatic cancer (PC), a disease which kills approximately 40,000 patients each year in the US, has successfully evaded several therapeutic approaches including the promising immunotherapeutic strategies. Irreversible electroporation (IRE) is a non-thermal ablation technique that induces tumor cell death without destruction of adjacent collagenous structures, thus enabling the procedure to be performed in tumors very close to blood vessels. Unlike thermal ablation techniques, IRE results in gradual apoptotic cell death, along with immediate ablation induced necrosis, and is currently in clinical use for selected patients with locally advanced PC. An ablative, non-target specific procedure like IRE can induce a myriad of responses in the tumor microenvironment. A few studies have addressed the effects of IRE on tumor growth in other tumor types, but none have focused on PC. We have developed a syngeneic mouse model of PC in which subcutaneous (SQ) and orthotopic tumors can be successfully treated with IRE in a highly controlled setting, facilitating various longitudinal studies post procedure. This animal model serves as a robust system to study the effects of IRE and ways to improve the clinical efficacy of IRE.

Entities:  

Mesh:

Year:  2018        PMID: 29939178      PMCID: PMC6101643          DOI: 10.3791/57265

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  20 in total

1.  Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation.

Authors:  Edward W Lee; Christopher T Loh; Stephen T Kee
Journal:  Technol Cancer Res Treat       Date:  2007-08

2.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

3.  Activation of dendritic cells by local ablation of hepatocellular carcinoma.

Authors:  Mona Y Ali; Christian F Grimm; Marcus Ritter; Leonhard Mohr; Hans-Peter Allgaier; Robert Weth; Wulf O Bocher; Katja Endrulat; Hubert E Blum; Michael Geissler
Journal:  J Hepatol       Date:  2005-06-20       Impact factor: 25.083

Review 4.  A review of basic to clinical studies of irreversible electroporation therapy.

Authors:  Chunlan Jiang; Rafael V Davalos; John C Bischof
Journal:  IEEE Trans Biomed Eng       Date:  2015-01       Impact factor: 4.538

5.  Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.

Authors:  Caroline Erös de Bethlenfalva-Hora; Joachim C Mertens; Anne-Christine Piguet; Joachim Kettenbach; Johannes Schmitt; Luigi Terracciano; Rosemarie Weimann; Jean-François Dufour; Andreas Geier
Journal:  Clin Sci (Lond)       Date:  2014-02       Impact factor: 6.124

6.  Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.

Authors:  Robert C G Martin; Kelli McFarland; Susan Ellis; Vic Velanovich
Journal:  Ann Surg Oncol       Date:  2012-11-06       Impact factor: 5.344

7.  Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination.

Authors:  Michal Safran; William Y Kim; Andrew L Kung; James W Horner; Ron A DePinho; William G Kaelin
Journal:  Mol Imaging       Date:  2003-10       Impact factor: 4.488

8.  Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response.

Authors:  Alessandro Zerbini; Massimo Pilli; Diletta Laccabue; Guido Pelosi; Atim Molinari; Elisa Negri; Simona Cerioni; Francesco Fagnoni; Paolo Soliani; Carlo Ferrari; Gabriele Missale
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

9.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer.

Authors:  Anna Maria Fietta; Monica Morosini; Ileana Passadore; Alessandro Cascina; Paola Draghi; Roberto Dore; Sandro Rossi; Ernesto Pozzi; Federica Meloni
Journal:  Hum Immunol       Date:  2009-03-27       Impact factor: 2.850

View more
  3 in total

1.  Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.

Authors:  Jayanth S Shankara Narayanan; Partha Ray; Tomoko Hayashi; Thomas C Whisenant; Diego Vicente; Dennis A Carson; Aaron M Miller; Stephen P Schoenberger; Rebekah R White
Journal:  Cancer Immunol Res       Date:  2019-08-13       Impact factor: 11.151

2.  Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model.

Authors:  Jayanth Surya Narayanan Shankara Narayanan; Katie Frizzi; Suna Erdem; Partha Ray; David Jaroch; Bryan Cox; Steven Katz; Diego Vicente; Rebekah White
Journal:  Discov Oncol       Date:  2022-04-06

Review 3.  Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.

Authors:  Molly C Holbrook; Dakota W Goad; Valery Z Grdzelishvili
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.